Teva to sell Allergan’s UK & Ireland generics business for $770m

pharmafile | October 6, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva 

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.

The company completed its acquisition of Allergan’s generics business in August for $40.5 billion. It is now selling the UK and Ireland branches of the business to India’s Intas Pharmaceuticals. The sale was part of Teva’s deal with the European Commission to get approval for the acquisition of Allergan’s generics arm, which is known as Actavis Generics.

Greenhill & Co is Teva’s financial adviser, while Rothschild & Co is advising Intas. According to Teva, the sale is expected to close in the next three months.

Matt Fellows

Related Content


FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns

The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, …


Teva’s cancer drug Bendeka protected from generics until 2031, judge rules

A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe …


$63bn Allergan/AbbVie merger review could be delayed by coronavirus

The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles …

Latest content